HQY Stock Recent News
HQY LATEST HEADLINES
U.S. stocks settled higher on Friday, with the Dow Jones index gaining more than 400 points during the session following the release of jobs data.
Investors looking for stocks in the Medical Services sector might want to consider either Pediatrix Medical Group (MD) or HealthEquity (HQY). But which of these two companies is the best option for those looking for undervalued stocks?
Ollie's Bargain Outlet (OLLI) and HealthEquity (HQY) have implemented successful growth strategies that investors are surely looking for.
HealthEquity, Inc. HQY posted better-than-expected first-quarter results after Tuesday's closing bell.
Health savings accounts, better known as HSAs, are designed to help people pay for their healthcare and come with some tax advantages. In the video above, HealthEquity CEO Scott Cutler explains the pros and cons of HSAs and how they may be impacted by President Trump's "Big Beautiful Bill.
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
HealthEquity (HQY 9.01%) reported fiscal 2026 first quarter (ended April 30, 2025) earnings on June 3, 2025, delivering 15% year-over-year revenue growth and raising full-year guidance. Key milestones included a 19% increase in adjusted EBITDA to $140.2 million, sharp reductions in quarterly fraud costs, and notable progress advancing both AI-enabled member experiences and regulatory engagement for expanded Health Savings Account (HSA) usage.
Scott Cutler, HealthEquity CEO, joins 'Squawk Box' to discuss the company's quarterly earnings results, state of the HSA market, how the tax and spending bill in Congress would impact eligibility, implementation of AI, and more.
HealthEquity, Inc. (NASDAQ:HQY ) Q1 2026 Earnings Conference Call June 3, 2025 4:30 PM ET Company Participants James M. Lucania - CFO & Executive VP Jon Kessler - Former Director & Special Advisor Richard Putnam - Vice President of Investor Relations Scott R.
HealthEquity benefits from secular HSA growth and higher interest rates, with Q1 results beating expectations and guidance raised slightly. The core investment thesis is HQY's earnings power is highly levered to cash balances and long-term interest rates, with fixed-rate contracts providing visibility and future growth. Valuation is sensitive to long-term rate assumptions; fair value is $105–$115 per share, with the current price near $110 offering only modest upside.